NCT04399785

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Phase II Study for Combination of Camrelizumab and Stereotacic Radiotherapy in the First-line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Xingchen Peng · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, single-center, open-label, phase II clinical study for patients with recurrent or metastatics quamous cell carcinoma of the head and neck.

Conditions

• Head and Neck Squamous Cell Carcinoma

Interventions

Type	Name	Description
OTHER	Camrelizumab and SBRT	Camrelizumab: 200mg every 3 weeks; SBRT

Timeline

• Start date: 2020-06-01
• Primary completion: 2021-12-01
• Completion: 2022-06-01
• First posted: 2020-05-22
• Last updated: 2020-05-22

Locations

1 site across 1 country: China